Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tularik Inc.
Headquarters: CA, United States of America
Website: N/A
Year Founded: 1991
Status: Acquired
BioCentury | May 14, 2021
Emerging Company Profile
Flare: Using ‘switch sites’ to modulate previously intractable transcription factors
Emerging Company Profile: With $82M series A, Third Rock-backed start-up uses structural insights into factors’ conformations
BioCentury | Nov 15, 2019
Financial News
Atomwise JV raises $14.5M series A to advance AI-discovered candidates
BioCentury | Mar 9, 2015
Finance
Column's creations
How The Column Group's long-term strategy yielded three wins
BioCentury | Oct 14, 2013
Strategy
Reviving Merck
Why it will take years to see Perlmutter's effect on R&D at Merck
BioCentury | Jun 18, 2012
Finance
Leaders, not CEOs
Cancer antibody play Igenica to reach clinic with $33M series C round
BioCentury | Aug 29, 2011
Emerging Company Profile
Novira: Capsid counterattack
Novira developing therapeutics against viral capsids for HBV, HIV
BioCentury | Jul 4, 2011
Finance
Virtual Velocity
CMEA Capital launches Velocity, a virtual drug development company
BioCentury | Mar 22, 2010
Product Development
Playing turnabout
NGM Biopharm seeks diabetes drug targets to reproduce effects of gastric banding
Items per page:
1 - 10 of 172